期刊文献+

靶向MTH1治疗肿瘤的研究进展 被引量:4

Progress in treatment of cancer targeting MTH1
在线阅读 下载PDF
导出
摘要 MTH1(mut T homolog1)是Mut T的同源酶,是一种核苷酸焦磷酸酶,主要参与DNA损伤修复过程,尤其在肿瘤细胞的DNA复制过程中发挥着重要角色。最新的研究表明,MTH1可以清除肿瘤细胞中受损DNA功能结构的氧化构件,使得肿瘤细胞继续分裂与增殖,从而维持肿瘤细胞的生存,而更为重要的是正常细胞不需要MTH1,因此,MTH1有可能只与异常的细胞生长密切相关,这使得MTH1作为治疗靶点成为人们关注的焦点。该文着重对MTH1与肿瘤关系最新的研究成果进行综述,探讨MTH1维持肿瘤生长的相关机制及其与肿瘤治疗的关系,为靶向MTH1治疗肿瘤提供新的思路,为肿瘤研究工作者提供重要参考。 MTH1( Mut T Homolog1) as Mut T homologous enzyme,is a nucleotide pyrophosphatase,mainly involved in DNA damage repair process,especially plays an important role in the process of DNA replication in tumor cells. Recent studies have found that MTH1's function is responsible for the development of a variety of tumors. Studies have shown that,MTH1 can remove tumor cells' oxidative DNA elements detrimental to the functional structure, protecting tumor cell division and proliferation,maintaining tumor cell survival,however,normal cells do not need MTH1. Therefore,MTH1 may be only closely associated with abnormal cell growth. This makes MTH1 as therapeutic targets that have been paid much attention. This article reviewed the relationship of MTH1 and tumor,discussed the mechanisms of MTH1 in tumor growth MTH1 and tumor treatment,so as to provide reference for clinical research and treatment of tumor.
出处 《中国药理学通报》 CAS CSCD 北大核心 2015年第9期1199-1201,共3页 Chinese Pharmacological Bulletin
基金 国家自然科学基金项目资助(No 81173174) 教育部博士点基金(No 20113237110008) 2013年江苏高校优秀科技创新团队计划
关键词 MTH1 肿瘤 分子机制 DNA复制 氧化损伤 治疗策略 MTH1 tumor molecular mechanisms DNA replication oxidative damage therapy strategies
作者简介 沈颖(1992-),女,硕士生,研究方向:肿瘤药物治疗及其机制,E-mail:shen123y@yeah.net; 陆茵(1963-),女,博士,教授,博士生导师,研究方向:活血化瘀中药及其复方抗肿瘤血管生成及对肿瘤转移、肿瘤微环境的影响,通讯作者,Tel:025-86798154,E—mail:luyingreen@126.com.
  • 相关文献

参考文献25

  • 1Xu M,Shao J G,Zeng Y X.Molecular classification and molecular targeted therapy of cancer[J].Front Med,2013,7(2):147-9.
  • 2Gad H,Koolmeister T,Jemth A S,et al.MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool[J].Nature,2014,508(7495):215-21.
  • 3Rich T,Aellen R L,Wyllie A H,Defying death after DNA damage[J].Nature,2000,407(6805):777-83.
  • 4Svensson L M,Jemth A S,Desroses M,et al.Crystal structure of human MTH1 and the 8-oxo-dGMP productcomplex[J].FEBS Lett,2011,585(16):2617-21.
  • 5Borrego S,Vazquez A,Dasi F,et al.Oxidative stress and DNA damage in human gastric carcinoma:8-Oxo-7'8-dihydro-2'-deoxyguanosine(8-oxo-dG)as a possible tumor marker[J].Int J Mol Sci,2013,14(2):3467-86.
  • 6Morak M,Massdorf T,Sykora H,et al.First evidence for digenic inheritance in hereditary colorectal cancer by mutations in the base excision repair genes[J].Eur J Cancer,2010,47(7):1046-55.
  • 7Kennedy C H,Cueto R,Belinsky S A,et al.Overexpression of hMTH1 mRNA:a molecular marker of oxidative stress in lung cancer cells[J].FEBS Lett,1998,429(1):17-20.
  • 8Takama F,Kanuma T,Wang D,et al.Mutation analysis of the hMTH1 gene in sporadic human ovarian cancer[J].Int J Oncol,2000,17(3):467-71.
  • 9Helleday T.Cancer phenotypic lethality,exemplified by the non-essential MTH1 enzyme being required for cancer survival[J].Oncol ESMO,2014,25(7):1253-5.
  • 10Nakabeppu Y.Regulation of intracellular localization of human MTH1,OGG1,and MYH proteins for repair of oxidative DNA damage[J].Prog Nucl Acid Res Molecul Biol,2001,68:75-94.

二级参考文献9

  • 1Belani C P,Eckardt J.Development of docetaxel in advanced non-small-cell lung cancer[J].Lung Cancer,2004,46(2):S3-11.
  • 2Pelicano H,Carney D,Huang P.ROS stress in cancer cells and therapeutic implications[J].Drug Resist Updat,2004,7(2):97-110.
  • 3Wang GYS,Abrell L M,Avelar A,et al.New hirsutane-based sesquiterpenes from salt water cultures of a marine sponge-derived fungus and the terrestrial fungus coriolus consors[J].Tetrahedron,1998,54(26):7335-42.
  • 4Saijo N,Nishio K,Ohta S,et al.Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan,with emphasis on taxanes[J].Cancer Chemother Pharmacol,1996,38:S11-5.
  • 5Gottesman M M,Fojo T,Bates S E.Multidrug resistance in cancer:role of ATP-dependent transporters[J].Nat Rev Cancer,2002,2(1):48-58.
  • 6Trachootham D,Zhang H,Zhang W,et al.Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism[J].Blood,2008,112(5):1912-22.
  • 7王巍,安达正晃,周晋.ROS在小白菊内酯诱导MM细胞凋亡中的作用[J].中国药理学通报,2009,25(1):92-94. 被引量:7
  • 8李勇,李铁库,温士旺,张月峰,田子强,史清文,铃木信夫.土木香中纯化的五种倍半萜类化合物抑制肿瘤增殖活性的研究[J].中国药理学通报,2010,26(1):112-115. 被引量:10
  • 9谢松强,李骞,张亚宏,王建红,赵瑾,王超杰.萘酰亚胺-多胺缀合物NNINspm通过PI_3 K/Akt信号通路诱导肝癌细胞凋亡[J].中国药理学通报,2010,26(2):169-174. 被引量:19

共引文献9

同被引文献45

  • 1NAM S K,YUN S,KOH J,et al.BRAF,PIK3CA,and HER2 oncogenic alterations according to KRAS mutation status in advanced colorectal cancers with distant metastasis[J/OL].PLoS One,2016,11(3):e0151865[2016-07-25].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4798471/.
  • 2LEE B,LEE T,LEE S H,et al.Clinicopathologic characteristics of EGFR,KRAS,and ALK alterations in 6,595 lung cancers[J].Oncotarget,2016,7(17):.
  • 3CHANG L,WANG G,JIA T,et al.Armored long non-coding RNA MEG3 targeting EGFR based on recombinant MS2 bacteriophage virus-like particles against hepatocellular carcinoma[J].Oncotarget,2016,7(17):23988-24004.
  • 4VAN D P B,BOONSTRA M C,SLOOTER M D,et al.EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer[J/OL].J Control Release,2016,229:93-105[2016-07-25].http://www.sciencedirect.com/science/article/pii/S0168365916301481.
  • 5ATIQ R,HERTZ R,ELDAD S,et al.Suppression of B-Raf(V600E) cancers by MAPK hyper-activation[J].Oncotarget,2016,7(14):18694-18704.
  • 6RAFAEL C,GILBERTO D C J,IGNACIO G B,et al.BRAF mutations in non-small cell lung cancer:has finally Janus opened the door?[J/OL].Crit Rev Oncol Hematol,2016,101:32-39[2016-07-25].http://www.croh-online.com/article/S1040-8428(16)30036-1/abstract.
  • 7ZITO M F,MORABITO A,GRIDELLI C,et al.Crizotinib response in a late relapse of ALK-positive lung adenocarcinoma[J/OL].Appl Immunohistochem Mol Morphol,2016(ahead of print)[2016-07-25].http://journals.lww.com/appliedimmunohist/pages/articleviewer.aspx?year=9000&issue=00000&article=99105&type=abstract.
  • 8FAN T,SONG Y J,LIU X L.Adenocarcinoma of the lung with concomitant ALK fusion gene and EGFR gene mutation:a case report and literature review[J/OL].Mol Clin Oncol,2016,4(2):203-205[2016-07-25].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4733966/.
  • 9TANAKA H,TAIMA K,MORIMOTO T,et al.Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status[J/OL].BMC Res Notes,2016,9(1):173[2016-07-25].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794901/.
  • 10KIM D W,MEHRA R,TAN D S,et al.Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1):updated results from the multicentre,open-label,phase 1 trial[J].Lancet Oncol,2016,17(4):452-463.

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部